Pancreatic cancer has long been one of the most difficult cancers to treat. Survival rates remain grim, with only about 13% of patients alive five years after diagnosis, and for a specific genetic subset of the disease, there are currently no approved targeted therapies at all. That is the backdrop for a new clinical agreement announced today between IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a South San Francisco-based precision oncology company, and F. Hoffmann-La Roche Ltd, the Swiss pharmaceutical subsidiary of one of the world’s largest and most established oncology-focused drug developers.
The two companies have agreed to combine their respective experimental drugs in a clinical trial targeting pancreatic ductal adenocarcinoma (PDAC) in patients whose tumors carry a specific genetic alteration called MTAP deletion. PDAC is the most common form of pancreatic cancer. MTAP deletion is a genetic change that occurs in the tumor’s DNA and is estimated to affect up to 40% of PDAC cases. Nearly all tumors with this deletion also carry mutations in a gene called RAS, which plays a key role in driving cancer cell growth. The combination of these two genetic features defines a patient population with a particularly high unmet medical need and, to date, no approved drugs designed specifically for them.
The drugs being tested together are IDE892, developed by IDEAYA, and RG6505, developed by Roche. To understand why this pairing makes scientific sense, it helps to know a little about how each drug works. IDE892 is a PRMT5 inhibitor. PRMT5 is an enzyme that cancer cells with MTAP deletion become unusually dependent on to survive, because the deletion disrupts a related cellular pathway. Blocking PRMT5 is thought to exploit that dependency. RG6505 is a pan-RAS inhibitor, meaning it targets the abnormal RAS protein that drives tumor growth in most of these patients. Combining the two is an approach known as synthetic lethality, a strategy where two separate vulnerabilities in cancer cells are targeted simultaneously. The idea is that attacking both at once can be far more effective than either drug alone, because the cancer cell has fewer ways to compensate or escape. Both drugs are currently in Phase 1 clinical trials.
IDEAYA will sponsor and run the combination trial, while Roche will supply its compound. Both companies will govern the study jointly and retain their own commercial rights to their respective drugs. There was no upfront cash payment disclosed. The agreement also includes the option to eventually expand the study to a three-drug combination that would add IDE397, IDEAYA’s MAT2A inhibitor, a third agent also designed to exploit MTAP deletion through a different mechanism.
For a clinical-stage biotech like IDEAYA, landing a partner like Roche carries real weight. Large pharmaceutical companies have the scientific infrastructure, global reach, and regulatory experience that smaller companies simply cannot replicate on their own. When a company of that scale chooses to combine one of its own experimental drugs with a partner’s asset, it signals a level of scientific conviction in the underlying approach. It also brings shared resources and credibility to a trial that might otherwise take years longer to get off the ground. This kind of collaboration does not replace IDEAYA’s own work, but it amplifies the chances of reaching patients faster and more efficiently.
The announcement arrived during a busy week for IDEAYA. The company also presented positive Phase 2/3 data from its OptimUM-02 trial at the American Society of Clinical Oncology conference, relating to darovasertib, a separate drug targeting metastatic uveal melanoma, a rare eye cancer. Plans for a New Drug Application filing with the FDA for that program are expected in the second half of 2026. Following the ASCO presentation, Cantor Fitzgerald reiterated its Overweight rating on the company, noting investor interest in IDEAYA’s PRMT5 and MTAP-deletion pathway work as a foundation for potential RAS and KRAS combinations in pancreatic and lung cancers.
The Roche collaboration adds a new dimension to a pipeline that is increasingly defined by the company’s focus on a specific genetic vulnerability. MTAP deletion appears across multiple tumor types, not just pancreatic cancer, and IDEAYA has built several programs around it. The agreement with Roche is a meaningful step toward testing whether targeting that vulnerability in combination with RAS inhibition can translate from scientific theory into clinical results for patients who currently have very few options.
